Vesalio announces it has successfully secured a Class A financing round. The proceeds will be utilized to support the ongoing US IDE stroke study, establish US infrastructure, expand its innovative product portfolio, and scale international business.
Vesalio announces another key milestone to support entry into the US neurovascular thrombectomy market. Enrollment has commenced in the Vesalio CLEAR acute ischemic stroke FDA IDE clinical trial utilizing the NeVaTM thrombectomy technology platform.
Vesalio announces it has accomplished a key FDA IDE study milestone to support entry into the US neurovascular market. Enrollment in the VITAL 1 clinical trial, assessing the company’s NeVa VS™ technology in the treatment of symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage (aSAH), has been completed.
As our customer and partner list lengthens and our geographical reach expands, we need new team members to join us in our exciting journey. We are looking for clinically oriented commercial profiles driven to deliver results.
Vesalio reports it has obtained an FDA 510k clearance and its 4th CE approval. The FDA 510k indication is for the removal of thrombi in peripheral blood vessels.
Vesalio reports it has surpassed 2,500 clinical cases with the NeVa™ neuro-thrombectomy platform. Physicians have evaluated the Neva Drop Zone™ technology with enthusiasm as it has shown a unique capability of removing the full spectrum of clot types in large vessel occlusion ischemic stroke.
Vesalio announces it has executed additional exclusive distribution agreements in Europe, Latin America, Asia, and the Middle East. With these new partnerships, the NeVa™ Thrombectomy System has gained market coverage in 53 countries.
On January 22 and 23, a diverse group of physicians from 8 different countries trained on new approaches for clot retrieval with the NeVa™ Drop Zone Retrieval Technique at the Vesalio Clot Interaction Workshops that took place at the Vall d’Hebron Research Institute.
Vesalio’s distributor partner in Poland, MedTim sp. A.o.o. was proud to sponsor #AcuteIschemicStroke courses organized in the Warsaw and Masovian Voivodship hospitals. During the courses (December 6-7, 2019 and January 17-18, 2020), our Polish team presented #NeVa to physicians #thrombectomy and provided hands-on experience using Vesalio’s proprietary silicone flow model. Thanks to all physicians and…
As the end of 2019 approaches, we reflect with pride and gratitude on what we achieved: We saw the publication of our First in Man data and initiated our regulatory enabling studies, We received our 2nd CE mark on the expanded #NeVa platform, including designs with more Drop Zones, We organized 5 Vesalio Clot Interaction…